Abstract Number: 1663 • 2019 ACR/ARP Annual Meeting
Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…Abstract Number: 1667 • 2019 ACR/ARP Annual Meeting
Long Term Outcome of Hydralazine-Associated Vasculitis
Background/Purpose: Hydralazine associated vasculitis (HAV) is rare but with potentially detrimental complications, affecting different organ systems. Most case series described short term disease course. Hence,…Abstract Number: 1668 • 2019 ACR/ARP Annual Meeting
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Background/Purpose: The long-term features of granulomatosis with polyangiitis (GPA), a systemic small-vessel ANCA-associated necrotizing vasculitis, have been mainly reported in small patient series. The aim…Abstract Number: 1669 • 2019 ACR/ARP Annual Meeting
Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis
Background/Purpose: Mizoribine (MZR) is an immunosuppressant working as an inhibitor of purine synthesis, which mechanism of action is similar to mycophenolate mofetil. MZR is approved…Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV). The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…Abstract Number: 1673 • 2019 ACR/ARP Annual Meeting
Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial
Background/Purpose: Overall mortality in ANCA-associated vasculitides (AAVs) over the last two decades has been reported to be decreasing with the use of immunosuppressive therapies. However,…Abstract Number: 1674 • 2019 ACR/ARP Annual Meeting
Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
Background/Purpose: To identify demographic and clinical risk factors for mortality in patients with ANCA-associated vasculitis (AAV) who were followed-up in a Latin-American Tertiary Referral Hospital.Methods:…Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…Abstract Number: 1676 • 2019 ACR/ARP Annual Meeting
Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?
Background/Purpose: Patients with rheumatic diseases are often at risk for opportunistic infections given the combination of disease manifestations and immunosuppressive treatment regimens, but the rates…Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…
ACR Meeting Abstracts